

CITATION REPORT

List of articles citing

The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway

DOI: 10.18632/aging.100160

Aging, 2010, 2, 344-52.

Source: <https://exaly.com/paper-pdf/87779208/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
266	apoB and apobec1, two genes key to lipid metabolism, are transcriptionally regulated by p53. <i>Cell Cycle</i> , 2010 , 9, 3785-3794	4.7	25
265	p53: The pivot between cell cycle arrest and senescence. <i>Cell Cycle</i> , 2010 , 9, 4262-3	4.7	12
264	Are the conspicuous interdependences of fecundity, longevity and cognitive abilities in humans caused in part by p53?. <i>Cell Cycle</i> , 2010 , 9, 3438-41	4.7	7
263	Myc, Cdk2 and cellular senescence: Old players, new game. <i>Cell Cycle</i> , 2010 , 9, 3679-3685	4.7	19
262	Life or death: p53-induced apoptosis requires DNA binding cooperativity. <i>Cell Cycle</i> , 2010 , 9, 4068-76	4.7	40
261	Weak p53 permits senescence during cell cycle arrest. <i>Cell Cycle</i> , 2010 , 9, 4323-7	4.7	116
260	The role of FAN1 nuclease in the Fanconi anemia pathway. <i>Cell Cycle</i> , 2010 , 9, 4259-60	4.7	5
259	Aven-uing between nuclear export and cell cycle arrest. <i>Cell Cycle</i> , 2010 , 9, 4043-4	4.7	
258	Cell cycle control of cell death in yeast. <i>Cell Cycle</i> , 2010 , 9, 4046	4.7	7
257	p53 and senescence: A little goes a long way. <i>Cell Cycle</i> , 2010 , 9, 4050-1	4.7	9
256	E2F1 regulation by the APC/C. <i>Cell Cycle</i> , 2010 , 9, 4044-5	4.7	
255	ArrestinQthe hedgehog: Shh limits its own signaling via EArrestin1. <i>Cell Cycle</i> , 2010 , 9, 4260-1	4.7	1
254	A new FAN of the stalled replication fork. <i>Cell Cycle</i> , 2010 , 9, 4261-2	4.7	
253	InhibitING entry into S phase and cell cycle progression. <i>Cell Cycle</i> , 2010 , 9, 4045-6	4.7	
252	Toward the mechanisms preventing merotelic kinetochore-microtubule attachments. <i>Cell Cycle</i> , 2010 , 9, 4048-9	4.7	1
251	Prevention of merotelic chromosome attachments by the monopolin complex. <i>Cell Cycle</i> , 2010 , 9, 4258	4.7	1
250	Ribosomal protein L37 and the p53 network. <i>Cell Cycle</i> , 2010 , 9, 4259	4.7	5

249	Purification and nucleotide excision repair system: Implications in cellular response to ultraviolet C radiation-induced DNA damage and chemoresistance in malignant cells. <i>Cell Cycle</i> , 2010 , 9, 4262	4-7	3
248	Greatwall in control of recovery. <i>Cell Cycle</i> , 2010 , 9, 4264-5	4-7	6
247	Histone genes, DNA replication, apoptosis and aging: What are the connections?. <i>Cell Cycle</i> , 2010 , 9, 4047-8	4-7	37
246	Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program. <i>Cell Cycle</i> , 2010 , 9, 3151-6	4-7	119
245	Increasing healthy lifespan by suppressing aging in our lifetime: preliminary proposal. <i>Cell Cycle</i> , 2010 , 9, 4788-94	4-7	51
244	Inflammation and p53: A Tale of Two Stresses. 2011 , 2, 503-16		125
243	Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. <i>Cell Cycle</i> , 2011 , 10, 4230-6	4-7	267
242	Genotoxic stress-mediated cell cycle activities for the decision of cellular fate. <i>Cell Cycle</i> , 2011 , 10, 3239-49	4-7	19
241	Stress responses of human dermal fibroblasts exposed to zinc pyrithione. 2011 , 204, 164-73		27
240	Cell cycle arrest is not senescence. <i>Aging</i> , 2011 , 3, 94-101	5-6	156
239	Hormesis does not make sense except in the light of TOR-driven aging. <i>Aging</i> , 2011 , 3, 1051-62	5-6	63
238	Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor. <i>Oncotarget</i> , 2011 , 2, 948-57	3-3	97
237	Dysregulated p53 inhibits expression of Ink4a/arf, blocks senescence, and promotes malignant conversion of keratinocytes. 2011 , 6, e21877		27
236	High glucose-mediated oxidative stress impairs cell migration. 2011 , 6, e22865		95
235	Pharmacologic activation of p53 by small-molecule MDM2 antagonists. 2011 , 17, 560-8		73
234	Control of p53 and NF- κ B signaling by WIP1 and MIF: role in cellular senescence and organismal aging. 2011 , 23, 747-52		82
233	mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. <i>Cell Cycle</i> , 2011 , 10, 3658-77	4-7	121
232	mTOR complex 2 signaling and functions. <i>Cell Cycle</i> , 2011 , 10, 2305-16	4-7	378

231	Metabolic regulation by p53. 2011 , 89, 237-45		239
230	The expanding relevance of nuclear mTOR in carcinogenesis. <i>Cell Cycle</i> , 2011 , 10, 3849-52	4-7	15
229	The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors. <i>Cell Cycle</i> , 2011 , 10, 2295-8	4-7	21
228	Recent advances in the therapeutic perspectives of Nutlin-3. 2011 , 17, 569-77		135
227	A GSK-3-mediated transcriptional network maintains repression of immediate early genes in quiescent cells. <i>Cell Cycle</i> , 2011 , 10, 3072-7	4-7	24
226	Gene expression signature of c-MYC-immortalized human fibroblasts reveals loss of growth inhibitory response to TGF β . <i>Cell Cycle</i> , 2011 , 10, 2540-8	4-7	10
225	Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. <i>Cell Cycle</i> , 2011 , 10, 3003-15	4-7	71
224	ATM-dependent ERK signaling via AKT in response to DNA double-strand breaks. <i>Cell Cycle</i> , 2011 , 10, 481-91	4-7	66
223	p63 promotes cellular quiescence via induction and activation of Notch3. <i>Cell Cycle</i> , 2011 , 10, 3111-8	4-7	17
222	Hdm2- and proteasome-dependent turnover limits p21 accumulation during S phase. <i>Cell Cycle</i> , 2011 , 10, 2714-23	4-7	9
221	Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. <i>Cell Cycle</i> , 2011 , 10, 100-7	4-7	47
220	A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. 2012 , 19, 713-21		101
219	Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells. <i>Cell Cycle</i> , 2012 , 11, 1393-9	4-7	31
218	Suppression of replicative senescence by rapamycin in rodent embryonic cells. <i>Cell Cycle</i> , 2012 , 11, 2402-7	4-7	70
217	The role of D-GADD45 in oxidative, thermal and genotoxic stress resistance. <i>Cell Cycle</i> , 2012 , 11, 4222-4	4-7	32
216	Rapalogs in cancer prevention: anti-aging or anticancer?. 2012 , 13, 1349-54		66
215	Hypoxia and gerosuppression: the mTOR saga continues. <i>Cell Cycle</i> , 2012 , 11, 3926-31	4-7	28
214	Death-associated proliferation kinetic in normal and transformed cells. <i>Cell Cycle</i> , 2012 , 11, 1512-6	4-7	3

213	p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. <i>Cell Cycle</i> , 2012 , 11, 4579-88	4-7	73
212	AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. 2012 , 31, 1949-62		163
211	Transcriptional regulation of gene expression during osmotic stress responses by the mammalian target of rapamycin. 2012 , 40, 4368-84		33
210	Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205. <i>Cell Cycle</i> , 2012 , 11, 1235-46	4-7	50
209	Persistent DNA damage caused by low levels of mitomycin C induces irreversible cell senescence. <i>Cell Cycle</i> , 2012 , 11, 3132-40	4-7	36
208	Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. <i>Cell Cycle</i> , 2012 , 11, 4642-9	4-7	77
207	Putting the brakes on p53-driven apoptosis. <i>Cell Cycle</i> , 2012 , 11, 4122-8	4-7	17
206	Morphological, molecular and functional differences of adult bone marrow- and adipose-derived stem cells isolated from rats of different ages. 2012 , 318, 2034-48		30
205	Hypoxia suppresses conversion from proliferative arrest to cellular senescence. 2012 , 109, 13314-8		141
204	Senescence and quiescence induced compromised function in cultured macrophages. 2012 , 33, 7497-507		20
203	MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. 2012 , 31, 752-63		53
202	Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. 2012 , 26, 841-70		91
201	Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. 2012 , 16, 1563-72		37
200	Controversial aspects of oncogene-induced senescence. <i>Cell Cycle</i> , 2012 , 11, 4147-51	4-7	29
199	Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. 2012 , 19, 107-20		1843
198	Necdin, a p53-target gene, is an inhibitor of p53-mediated growth arrest. 2012 , 7, e31916		10
197	Evolutionary conservation and network structure characterize genes of phenotypic relevance for mitosis in human. 2012 , 7, e36488		4
196	REDD1 protects osteoblast cells from gamma radiation-induced premature senescence. 2012 , 7, e36604		34

195	Recent discoveries in the cycling, growing and aging of the p53 field. <i>Aging</i> , 2012 , 4, 887-93	5.6	18
194	Staying alive: metabolic adaptations to quiescence. <i>Cell Cycle</i> , 2012 , 11, 1680-96	4.7	146
193	Status of mTOR activity may phenotypically differentiate senescence and quiescence. 2012 , 33, 597-604		44
192	Hormesis: why it is important to biogerontologists. 2012 , 13, 215-35		76
191	p53 induces transcriptional and translational programs to suppress cell proliferation and growth. 2013 , 14, R32		80
190	MEK drives cyclin D1 hyper-elevation during geroconversion. 2013 , 20, 1241-9		65
189	Metabolic regulation by p53 family members. 2013 , 18, 617-33		320
188	Lying low but ready for action: the quiescent muscle satellite cell. 2013 , 280, 4036-50		138
187	mTORC1 and p53: clash of the gods?. <i>Cell Cycle</i> , 2013 , 12, 20-5	4.7	63
186	Senescence regulation by mTOR. 2013 , 965, 15-35		31
185	Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells. 2013 , 53, 202-10		38
184	Cell senescence as both a dynamic and a static phenotype. 2013 , 965, 1-13		30
183	Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development. 2013 , 17, 12-29		175
182	Senescence regulation by the p53 protein family. 2013 , 965, 37-61		92
181	p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice. <i>Cell Cycle</i> , 2013 , 12, 122-32	4.7	14
180	MTOR-driven quasi-programmed aging as a disposable soma theory: blind watchmaker vs. intelligent designer. <i>Cell Cycle</i> , 2013 , 12, 1842-7	4.7	32
179	S6K in geroconversion. <i>Cell Cycle</i> , 2013 , 12, 3249-52	4.7	23
178	Aging is not programmed: genetic pseudo-program is a shadow of developmental growth. <i>Cell Cycle</i> , 2013 , 12, 3736-42	4.7	85

177	Major Signaling Pathways Involved in Breast Cancer. 2013 , 47-64		3
176	Dysregulation of the mTOR pathway in p53-deficient mice. 2013 , 14, 1182-8		24
175	The Oncogene LRF Stimulates Proliferation of Mesenchymal Stem Cells and Inhibits Their Chondrogenic Differentiation. 2013 , 4, 329-38		3
174	IL-6-STAT3 signaling and premature senescence. 2013 , 2, e25763		82
173	Selective anti-cancer agents as anti-aging drugs. 2013 , 14, 1092-7		36
172	Rapamycin induces pluripotent genes associated with avoidance of replicative senescence. <i>Cell Cycle</i> , 2013 , 12, 3841-51	4.7	18
171	Rapamycin regulates biochemical metabolites. <i>Cell Cycle</i> , 2013 , 12, 2454-67	4.7	6
170	CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion. <i>Cell Cycle</i> , 2013 , 12, 3063-9	4.7	84
169	p53 mutations associated with aging-related rise in cancer incidence rates. <i>Cell Cycle</i> , 2013 , 12, 2468-78	4.7	27
168	The significance of the senescence pathway in breast cancer progression. 2013 , 66, 491-5		17
167	p53 as an intervention target for cancer and aging. 2013 , 3,		39
166	Rapamycin extends life- and health span because it slows aging. <i>Aging</i> , 2013 , 5, 592-8	5.6	63
165	Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion. <i>Oncotarget</i> , 2014 , 5, 12715-27	3.3	29
164	Long term exposure to L-arginine accelerates endothelial cell senescence through arginase-II and S6K1 signaling. <i>Aging</i> , 2014 , 6, 369-79	5.6	23
163	Sustained activation of DNA damage response in irradiated apoptosis-resistant cells induces reversible senescence associated with mTOR downregulation and expression of stem cell markers. <i>Cell Cycle</i> , 2014 , 13, 1424-39	4.7	52
162	M(o)TOR of pseudo-hypoxic state in aging: rapamycin to the rescue. <i>Cell Cycle</i> , 2014 , 13, 509-15	4.7	39
161	Radiation-Induced Bystander Response: Mechanism and Clinical Implications. 2014 , 3, 16-24		20
160	Tumour suppressors and cellular senescence. 2014 , 66, 812-22		8

159	Ex vivo molecular rejuvenation improves the therapeutic activity of senescent human cardiac stem cells in a mouse model of myocardial infarction. 2014 , 32, 2373-85		52
158	Geroconversion: irreversible step to cellular senescence. <i>Cell Cycle</i> , 2014 , 13, 3628-35	4-7	92
157	Glucocorticoids induce senescence in primary human tenocytes by inhibition of sirtuin 1 and activation of the p53/p21 pathway: in vivo and in vitro evidence. 2014 , 73, 1405-13		60
156	The mitochondrial genome in aging and senescence. 2014 , 18, 1-15		48
155	PI3K/Akt/uncoupling protein 2 signaling pathway may be involved in cell senescence and apoptosis induced by angiotensin II in human vascular endothelial cells. 2014 , 41, 6931-7		17
154	Genetic ablation of solute carrier family 7a3a leads to hepatic steatosis in zebrafish during fasting. 2014 , 60, 1929-41		53
153	Modulators of cellular senescence: mechanisms, promises, and challenges from in vitro studies with dietary bioactive compounds. 2014 , 34, 1017-35		24
152	Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program. 2014 , 111, 8832-7		95
151	Signaling Networks Controlling Cellular Senescence. 2014 , 67-83		
150	p53 suppresses stress-induced cellular senescence via regulation of autophagy under the deprivation of serum. 2015 , 11, 1214-20		11
149	Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells. 2015 , 5, 17730		50
148	CD8+ T-cell senescence: no role for mTOR. 2015 , 43, 734-9		4
147	A novel pyrido-thieno-pyrimidine derivative activates p53 through induction of phosphorylation and acetylation in colorectal cancer cells. 2015 , 46, 342-50		12
146	Rejuvenating immunity: "anti-aging drug today" eight years later. <i>Oncotarget</i> , 2015 , 6, 19405-12	3-3	23
145	Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways. <i>Oncotarget</i> , 2015 , 6, 25755-69	3-3	69
144	p53-regulated autophagy is controlled by glycolysis and determines cell fate. <i>Oncotarget</i> , 2015 , 6, 23135-56		34
143	Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy. <i>Oncotarget</i> , 2015 , 6, 7040-52	3-3	12
142	Glioblastoma: molecular pathways, stem cells and therapeutic targets. 2015 , 7, 538-55		83

141	Human Periosteal Derived Stem Cell Potential: The Impact of age. 2015 , 11, 487-500		24
140	The Intricate Interplay between Mechanisms Underlying Aging and Cancer. 2015 , 6, 56-75		22
139	Cellular Mechanisms of Oxidative Stress and Action in Melanoma. 2015 , 2015, 481782		66
138	Quantitative analysis of male germline stem cell differentiation reveals a role for the p53-mTORC1 pathway in spermatogonial maintenance. <i>Cell Cycle</i> , 2015 , 14, 2905-13	4-7	8
137	Senescence in Oncogenesis: From Molecular Mechanisms to Therapeutic Opportunities. 2015 , 127-155		
136	Disruptive chemicals, senescence and immortality. 2015 , 36 Suppl 1, S19-37		26
135	Proteomic analysis reveals a role for Bcl2-associated athanogene 3 and major vault protein in resistance to apoptosis in senescent cells by regulating ERK1/2 activation. 2015 , 14, 1-14		23
134	Biomolecular bases of the senescence process and cancer. A new approach to oncological treatment linked to ageing. 2015 , 23, 125-38		17
133	Loss of p53-mediated cell-cycle arrest, senescence and apoptosis promotes genomic instability and premature aging. <i>Oncotarget</i> , 2016 , 7, 11838-49	3-3	44
132	Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway. <i>Aging</i> , 2016 , 8, 1102-14	5.6	72
131	MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53. <i>Oncotarget</i> , 2016 , 7, 75328-75338	3-3	22
130	Lysines in the tetramerization domain of p53 selectively modulate G1 arrest. <i>Cell Cycle</i> , 2016 , 15, 1425-38.7		9
129	p53 and the Carcinogenicity of Chronic Inflammation. 2016 , 6,		60
128	The cell fate: senescence or quiescence. 2016 , 43, 1213-1220		97
127	cMyc-p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response. <i>Cell Cycle</i> , 2016 , 15, 1267-75	4-7	11
126	Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects. 2017 , 64, 39-48		73
125	Induction of dormancy in hypoxic human papillomavirus-positive cancer cells. 2017 , 114, E990-E998		36
124	Cooperation between p21 and Akt is required for p53-dependent cellular senescence. 2017 , 16, 1094-1103		49

123	Herbal formula YYJD inhibits tumor growth by inducing cell cycle arrest and senescence in lung cancer. 2017 , 7, 4984			13
122	Effects of Ageing on Adaptive Immune Responses. 2017 , 21-33			
121	The Ageing Immune System and Health. 2017 ,			1
120	Cardiac Cell Senescence and Redox Signaling. 2017 , 4, 38			13
119	Autophagy and the Cell Cycle: A Complex Landscape. 2017 , 7, 51			97
118	A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein-protein interactions identifies a novel putative Mdm2-binding site in p53. 2017 , 15, 108			19
117	Shining the Light on Senescence Associated LncRNAs. 2017 , 8, 149-161			8
116	CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. 2018 , 34, 9-20			145
115	Rapamycin, proliferation and geroconversion to senescence. <i>Cell Cycle</i> , 2018 , 17, 2655-2665	4-7		33
114	p53 and metabolism: from mechanism to therapeutics. <i>Oncotarget</i> , 2018 , 9, 23780-23823	3-3		67
113	Current Progress in the Rejuvenation of Aging Stem/Progenitor Cells for Improving the Therapeutic Effectiveness of Myocardial Repair. 2018 , 2018, 9308301			12
112	mTOR Cross-Talk in Cancer and Potential for Combination Therapy. 2018 , 10,			78
111	Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence. 2018 , 10,			7
110	Doxorubicin and liposomal doxorubicin induce senescence by enhancing nuclear factor kappa B and mitochondrial membrane potential. 2019 , 232, 116677			8
109	A Bird@-Eye View of the Multiple Biochemical Mechanisms that Propel Pathology of Alzheimer@ Disease: Recent Advances and Mechanistic Perspectives on How to Halt the Disease Progression Targeting Multiple Pathways. 2019 , 69, 631-649			8
108	Senescent and apoptotic osteocytes and aging: Exercise to the rescue?. 2019 , 121, 255-258			13
107	mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53. 2019 , 38, 1639-1650			47
106	Inhibition of mTOR Signaling Enhances Maturation of Cardiomyocytes Derived From Human-Induced Pluripotent Stem Cells via p53-Induced Quiescence. 2020 , 141, 285-300			36

105	Osteocyte apoptosis: the roles and key molecular mechanisms in resorption-related bone diseases. 2020 , 11, 846		24
104	Targeting dormant tumor cells to prevent cancer recurrence. 2021 , 288, 6286-6303		18
103	Ageing and longevity genes in cardiovascular diseases. 2020 , 127, 120-131		10
102	Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?. 2021 , 16, 115-128		3
101	Herb-target virtual screening and network pharmacology for prediction of molecular mechanism of Danggui Beimu Kushen Wan for prostate cancer. 2021 , 11, 6656		7
100	Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 645593	5-7	102
99	Mitochondria and metabolic transitions in cardiomyocytes: lessons from development for stem cell-derived cardiomyocytes. 2021 , 12, 177		10
98	Senescence mechanisms and targets in the heart. 2021 ,		8
97	Tumor Dormancy: Implications for Invasion and Metastasis. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
96	The biological relevance of pigment epithelium-derived factor on the path from aging to age-related disease. 2021 , 196, 111478		2
95	The Δ 0p53 isoform inhibits p53-dependent eRNA transcription and enables regulation by signal-specific transcription factors during p53 activation. 2021 , 19, e3001364		3
94	p53 upregulation is a frequent response to deficiency of cell-essential genes. 2010 , 5, e15938		27
93	Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. 2011 , 6, e18588		84
92	Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin. 2011 , 6, e26126		31
91	Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. 2011 , 6, e28405		37
90	Androgen receptor drives cellular senescence. 2012 , 7, e31052		41
89	mTOR favors senescence over quiescence in p53-arrested cells. <i>Aging</i> , 2010 , 2, 327-8	5.6	10
88	Another "Janus paradox" of p53: induction of cell senescence versus quiescence. <i>Aging</i> , 2010 , 2, 329-30	5.6	15

87	Decision-making by p53 and mTOR. <i>Aging</i> , 2010 , 2, 324-6	5.6	22
86	p53, ROS and senescence in the control of aging. <i>Aging</i> , 2010 , 2, 471-4	5.6	158
85	Adult-onset, short-term dietary restriction reduces cell senescence in mice. <i>Aging</i> , 2010 , 2, 555-66	5.6	103
84	Unfolded p53 in the pathogenesis of Alzheimer's disease: is HIPK2 the link?. <i>Aging</i> , 2010 , 2, 545-54	5.6	39
83	Statin prevents chondrocyte aging and degeneration of articular cartilage in osteoarthritis (OA). <i>Aging</i> , 2010 , 2, 990-8	5.6	69
82	The p53 inducing drug dosage may determine quiescence or senescence. <i>Aging</i> , 2010 , 2, 748	5.6	27
81	mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging. <i>Aging</i> , 2010 , 2, 892-3	5.6	21
80	The DNA damage response: Balancing the scale between cancer and ageing. <i>Aging</i> , 2010 , 2, 900-7	5.6	48
79	Be quiet and you'll keep young: does mTOR underlie p53 action in protecting against senescence by favoring quiescence?. <i>Aging</i> , 2011 , 3, 3-4	5.6	19
78	DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. <i>Aging</i> , 2010 , 2, 924-35	5.6	142
77	SIRT-ain relief from age-inducing stress. <i>Aging</i> , 2011 , 3, 158-61	5.6	12
76	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <i>Aging</i> , 2011 , 3, 192-222	5.6	437
75	The implication of Sir2 in replicative aging and senescence in <i>Saccharomyces cerevisiae</i> . <i>Aging</i> , 2011 , 3, 319-24	5.6	18
74	Progeria, rapamycin and normal aging: recent breakthrough. <i>Aging</i> , 2011 , 3, 685-91	5.6	39
73	Hormesis, cell death and aging. <i>Aging</i> , 2011 , 3, 821-8	5.6	97
72	Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression. <i>Aging</i> , 2011 , 3, 1078-91	5.6	96
71	Chronological lifespan in stationary culture: from yeast to human cells. <i>Aging</i> , 2011 , 3, 1041-2	5.6	6
70	Molecular links between cellular senescence, longevity and age-related diseases - a systems biology perspective. <i>Aging</i> , 2011 , 3, 1178-91	5.6	106

69	Recent progress in targeting cancer. <i>Aging</i> , 2011 , 3, 1154-62	5.6	9
68	Molecular damage in cancer: an argument for mTOR-driven aging. <i>Aging</i> , 2011 , 3, 1130-41	5.6	72
67	Mitochondrial dysfunction and cell senescence--skin deep into mammalian aging. <i>Aging</i> , 2012 , 4, 74-5	5.6	18
66	Interaction between the Cockayne syndrome B and p53 proteins: implications for aging. <i>Aging</i> , 2012 , 4, 89-97	5.6	24
65	Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. <i>Aging</i> , 2012 , 4, 159-65	5.6	195
64	cep-1/p53-dependent dysplastic pathology of the aging <i>C. elegans</i> gonad. <i>Aging</i> , 2012 , 4, 256-69	5.6	29
63	Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?. <i>Aging</i> , 2012 , 4, 450-5	5.6	36
62	The mitochondria-targeted antioxidant SkQ1 but not N-acetylcysteine reverses aging-related biomarkers in rats. <i>Aging</i> , 2012 , 4, 686-94	5.6	37
61	Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. <i>Aging</i> , 2012 , 4, 709-146	5.6	114
60	Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells. <i>Aging</i> , 2012 , 4, 803-822	5.6	100
59	Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging. <i>Aging</i> , 2012 , 4, 899-916	5.6	40
58	Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development. <i>Aging</i> , 2013 , 5, 111-9	5.6	17
57	Role of p38 mitogen-activated protein kinase in vascular endothelial aging: interaction with Arginase-II and S6K1 signaling pathway. <i>Aging</i> , 2015 , 7, 70-81	5.6	28
56	To senesce or not to senesce: how primary human fibroblasts decide their cell fate after DNA damage. <i>Aging</i> , 2016 , 8, 158-77	5.6	7
55	Reduced SOD2 expression is associated with mortality of hepatocellular carcinoma patients in a mutant p53-dependent manner. <i>Aging</i> , 2016 , 8, 1184-200	5.6	25
54	A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers. <i>Oncotarget</i> , 2010 , 1, 405-22	3.3	22
53	Increased gene expression noise in human cancers is correlated with low p53 and immune activities as well as late stage cancer. <i>Oncotarget</i> , 2016 , 7, 72011-72020	3.3	13
52	Selective anticancer agents suppress aging in <i>Drosophila</i> . <i>Oncotarget</i> , 2013 , 4, 1507-26	3.3	30

51	A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers. <i>Oncotarget</i> , 2010 , 1, 405-422	3-3	27
50	Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma. <i>Oncotarget</i> , 2014 , 5, 3662-72	3-3	34
49	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. <i>Oncotarget</i> , 2011 , 2, 135-64	3-3	45 ⁶
48	Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity. <i>Oncotarget</i> , 2011 , 2, 109-12	3-3	17
47	Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. <i>Oncotarget</i> , 2011 , 2, 222-33	3-3	13 ¹
46	Connexin32 regulates hepatoma cell metastasis and proliferation via the p53 and Akt pathways. <i>Oncotarget</i> , 2015 , 6, 10116-33	3-3	26
45	Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. <i>Oncotarget</i> , 2011 , 2, 538-50	3-3	69
44	Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. <i>Oncotarget</i> , 2011 , 2, 610-26	3-3	38
43	NUAK2: an emerging acral melanoma oncogene. <i>Oncotarget</i> , 2011 , 2, 695-704	3-3	15
42	MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. <i>Oncotarget</i> , 2015 , 6, 8226-43	3-3	76
41	Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. <i>Oncotarget</i> , 2011 , 2, 1203-17	3-3	99
40	p53 attenuates AKT signaling by modulating membrane phospholipid composition. <i>Oncotarget</i> , 2015 , 6, 21240-54	3-3	32
39	NCIQ provocative questions on cancer: some answers to ignite discussion. <i>Oncotarget</i> , 2011 , 2, 1352-67	3-3	46
38	p53 and rapamycin are additive. <i>Oncotarget</i> , 2015 , 6, 15802-13	3-3	24
37	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. <i>Oncotarget</i> , 2012 , 3, 371-94	3-3	98
36	Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program). <i>Oncotarget</i> , 2015 , 6, 23238-48	3-3	50
35	Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells. <i>Oncotarget</i> , 2012 , 3, 601-7	3-3	13
34	Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. <i>Oncotarget</i> , 2012 , 3, 882-92	3-3	63

33	Wip1 phosphatase: between p53 and MAPK kinases pathways. <i>Oncotarget</i> , 2016 , 7, 31563-71	3.3	38
32	Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. <i>Oncotarget</i> , 2016 , 7, 12951-61	3.3	24
31	Cancer-associated S100P protein binds and inactivates p53, permits therapy-induced senescence and supports chemoresistance. <i>Oncotarget</i> , 2016 , 7, 22508-22	3.3	16
30	Advances in targeting signal transduction pathways. <i>Oncotarget</i> , 2012 , 3, 1505-21	3.3	39
29	Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. <i>Oncotarget</i> , 2016 , 7, 27511-26	3.3	22
28	Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes. <i>Oncotarget</i> , 2012 , 3, 1522-32	3.3	21
27	Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions. <i>Oncotarget</i> , 2012 , 3, 1711-24	3.3	35
26	Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival. <i>Oncotarget</i> , 2016 , 7, 31723-37	3.3	13
25	The IGF-1R/AKT pathway determines cell fate in response to p53. <i>Translational Cancer Research</i> , 2016 , 5, 664-675	0.3	17
24	Do p53 stress responses impact organismal aging?. <i>Translational Cancer Research</i> , 2016 , 5, 685-691	0.3	6
23	Amentoflavone Induces Autophagy and Modulates p53. <i>Cell Journal</i> , 2019 , 21, 27-34	2.4	9
22	Aging: A cell source limiting factor in tissue engineering. <i>World Journal of Stem Cells</i> , 2019 , 11, 787-802	5.6	11
21	P53 levels govern the choice between senescence and quiescence. <i>Aging</i> , 2010 , 2, 637-638	5.6	
20	Senescence. 2011 , 235-254		
19	Senescence. 2017 , 289-310		
18	In Cellular Senescence, the Third Circle of the Cell Life Network, p53 Acts Vital Role. 1-10		
17	[The mechanism of bone marrow-derived mesenchymal stem cells excessive senescence in severe aplastic anemia mouse model]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , 2017 , 38, 325-329	0.4	0
16	Long-term cardiovascular complications following sepsis: is senescence the missing link?. <i>Annals of Intensive Care</i> , 2021 , 11, 166	8.9	1

15	It's Getting Complicated-A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy.. <i>Frontiers in Cell and Developmental Biology</i> , 2022 , 10, 818744	5.7	2
14	A new insight into cell biological and biochemical changes through aging.. <i>Acta Histochemica</i> , 2022 , 124, 151841	2	4
13	Low Dose Chronic Angiotensin II Induces Selective Senescence of Kidney Endothelial Cells.. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 782841	5.7	1
12	Cell senescence, rapamycin and hyperfunction theory of aging.. <i>Cell Cycle</i> , 2022 , 1-12	4.7	4
11	Cell Senescence and Central Regulators of Immune Response.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
10	Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?. <i>Cellular and Molecular Biology Letters</i> , 2021 , 26, 53	8.1	1
9	Crosstalk between age accumulated DNA-damage and the SIRT1-AKT-GSK3 β axis in urine derived renal progenitor cells.		
8	Translation of Cellular Senescence to Novel Therapeutics: Insights From Alternative Tools and Models. <i>Frontiers in Aging</i> , 2022 , 3,	2.5	0
7	Evidence of sex differences in cellular senescence. 2022 , 120, 88-104		2
6	As expected, based on rapamycin-like p53-mediated gerosuppression, mTOR inhibition acts as a checkpoint in p53-mediated tumor suppression. 2022 , 9, 38-41		0
5	Cell overgrowth during G1 arrest triggers an osmotic stress response and chronic p38 activation to promote cell cycle exit.		0
4	Crosstalk between age accumulated DNA-damage and the SIRT1-AKT-GSK3 β axis in urine derived renal progenitor cells.		0
3	Regulation of Metastatic Tumor Dormancy and Emerging Opportunities for Therapeutic Intervention. 2022 , 23, 13931		0
2	Role of E2F transcription factor in oral cancer: Recent insight and advancements. 2023 , 92, 28-41		0
1	Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer. 2023 , 15, 2015		0